<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02357381</url>
  </required_header>
  <id_info>
    <org_study_id>SpringTMSUSPMOS 2014-01</org_study_id>
    <nct_id>NCT02357381</nct_id>
  </id_info>
  <brief_title>eNeura SpringTMS Post-Market Observational US Study of Migraine</brief_title>
  <acronym>ESPOUSE</acronym>
  <official_title>eNeura SpringTMS Post-Market Observational U.S. Study of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>eNeura, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>eNeura, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, prospective, non-randomized, single arm, open label, post-market,&#xD;
      observational study to evaluate the use of the eneura, springtms system in reduction of&#xD;
      migraine headache symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, non-randomized, single arm, multi-center observational study designed to&#xD;
      evaluate the use of the SpringTMS system in reducing the frequency of headache days.&#xD;
&#xD;
      Note: This is a NON-SIGNIFICANT RISK (NSR) study of a NON-SIGNIFICANT RISK (NSR) Device. It&#xD;
      is a post market study of a NSR device cleared by FDA through the 510(k) pre-market&#xD;
      notification process. The cleared indications for use are provided above. This NSR study is&#xD;
      designed to collect information on additional applications of the SpringTMS device. These&#xD;
      additional applications include:&#xD;
&#xD;
        1. Use of the device to evaluate the potential for regular use of sTMS to reduce the&#xD;
           frequency, severity, and/or duration of migraine.&#xD;
&#xD;
        2. Delivery of additional treatments (pulses) to evaluate the acute treatment efficacy of&#xD;
           breakthrough migraine attacks with and without aura.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2014</start_date>
  <completion_date type="Actual">July 1, 2016</completion_date>
  <primary_completion_date type="Actual">July 1, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Headache Days</measure>
    <time_frame>3 months</time_frame>
    <description>Reduction in mean headache days</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">263</enrollment>
  <condition>Headache</condition>
  <arm_group>
    <arm_group_label>TMS Treatment</arm_group_label>
    <description>TMS( transcranial magnetic stimulation) -treatment for headache</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>eNeura SpringTMS</intervention_name>
    <description>Single pulse magnetic stimulation for prevention and/or treatment of migraine headache with or without aura.</description>
    <arm_group_label>TMS Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        4-25 headache days per month (confirmed by 1-month baseline diary, minimum of 5 complete&#xD;
        headache-free days/month)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients 18 to 65 years of age;&#xD;
&#xD;
          2. Patients able to understand and communicate in English;&#xD;
&#xD;
          3. Migraine with or without aura;&#xD;
&#xD;
          4. 4-25 headache days per month (confirmed by 1-month baseline diary, minimum of 5&#xD;
             complete headache-free days/month);&#xD;
&#xD;
          5. Understand and willing to provide diary and survey data.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects will be excluded from participating in this trial if they meet any of the&#xD;
             following criteria&#xD;
&#xD;
               1. Severe co-existing disease having a life expectancy of less than 1 year;&#xD;
&#xD;
               2. Currently involved in any other investigational clinical trials that have not&#xD;
                  completed their primary endpoint or that may interfere with the SpringTMS study&#xD;
                  results;&#xD;
&#xD;
               3. Mental impairment or other conditions which may not allow the subject to&#xD;
                  understand the nature, significance and scope of the study and to cooperate with&#xD;
                  follow-up requirements;&#xD;
&#xD;
               4. Known drug and/or alcohol addiction or use of illicit substances;&#xD;
&#xD;
               5. Patients with epilepsy or history of seizure;&#xD;
&#xD;
               6. Severe active major depression or major psychiatric illness;&#xD;
&#xD;
               7. Concurrent use of other neurostimulation devices (Cefaly®, TENS, implantable&#xD;
                  devices);&#xD;
&#xD;
               8. Use of Botox® within past 4 months;&#xD;
&#xD;
               9. Extracranial nerve block (e.g. occipital, supraorbital) within past 3 months;&#xD;
&#xD;
              10. Use of Cefaly for prevention within past month;&#xD;
&#xD;
              11. Patients with metal containing implants as follows:&#xD;
&#xD;
        The SpringTMS may not be used in patients who have metals, conductive materials, or&#xD;
        metal-containing implants in their head, neck or upper body. Patients with implants that&#xD;
        are affected by a magnetic field should not use the SpringTMS. Examples of such implants&#xD;
        include:&#xD;
&#xD;
          -  Aneurysm clips or coils • Radioactive seeds&#xD;
&#xD;
          -  Cochlear implants • Magnetically programmable shunt valves&#xD;
&#xD;
          -  Cerebral spinal fluid shunts • Stents&#xD;
&#xD;
          -  Bullets or pellets lodged in the head or upper body • Metal plates, screws, staples or&#xD;
             sutures in skull, neck, shoulders, arms or hands&#xD;
&#xD;
          -  Filters • Metallic artificial heart valves&#xD;
&#xD;
          -  Electrodes • Facial tattoos with metallic ink Dental implants, fillings, or other&#xD;
             dental appliances are okay and are not affected by the device.&#xD;
&#xD;
        Note: although not explicitly excluded, safety and effectiveness have not been established&#xD;
        in pregnant women. Please defer to the judgment of the investigator when considering the&#xD;
        eligibility of this population.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David W Dodick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic , Phoenix,AZ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Headache Research and Treatment Program</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Headache Program</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Permanente Medical Group-Kaiser</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Center for Headache and Pain</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jefferson Headache Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>February 3, 2015</study_first_submitted>
  <study_first_submitted_qc>February 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2015</study_first_posted>
  <last_update_submitted>June 13, 2021</last_update_submitted>
  <last_update_submitted_qc>June 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

